{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:24:53Z","timestamp":1793532293894,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim International GmbH"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The quest for innovative pharmacologic interventions in idiopathic pulmonary fibrosis (IPF) is a challenging journey. The complexity of the disease demands a comprehensive approach that targets multiple cell types and pathways. This study examined the antifibrotic properties of nerandomilast, a preferential phosphodiesterase 4B inhibitor, focusing on its effects on myofibroblasts (MFs) and endothelial cells. Using cytokine-stimulated human IPF lung fibroblasts and RNA sequencing, we assessed the effects of nerandomilast on MF contractility, MF markers, and differentiation mechanisms. In addition, using human microvascular endothelial cells, we assessed endothelial barrier integrity and monocyte adhesion in a three-dimensional microfluidic chip. Our results show that nerandomilast significantly inhibited MF contractility and marker expression in cytokine-stimulated human IPF lung fibroblast cells. Treatment with nerandomilast significantly activated cAMP-associated pathways and G-protein\u2013coupled receptor signaling events while inhibiting mitogen-activated protein kinase signaling pathways and transforming growth factor \u03b2 signaling. Nerandomilast also significantly reduced microvascular permeability in cytokine-stimulated human lung microvascular endothelial cells. Finally, in an adeno-associated virus\u2013human diphtheria toxin receptor\/diphtheria toxin mouse model of acute lung injury, nerandomilast significantly inhibited total protein in lavage, total macrophages, neutrophils, cell count, and VCAM-1 expression. In summary, our results demonstrate that nerandomilast induces the dedifferentiation of human IPF lung MFs and diminishes their contractility in vitro by interfering with transforming growth factor \u03b2, mitogen-activated protein kinase phosphatase-1, and G-protein\u2013coupled receptor signaling pathways. It also mitigates vascular dysfunction by strengthening endothelial junctions and inhibiting adhesion protein expression. These findings highlight nerandomilast\u2019s potential therapeutic use in IPF by providing insights into its cellular and molecular actions.<\/jats:p>","DOI":"10.1165\/rcmb.2024-0614oc","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:59:31Z","timestamp":1744815571000},"page":"700-712","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":55,"title":["Insights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2823-7616","authenticated-orcid":false,"given":"Dennis","family":"Reininger","sequence":"first","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wolf","sequence":"additional","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph H.","family":"Mayr","sequence":"additional","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne L.","family":"Wespel","sequence":"additional","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Laufhaeger","sequence":"additional","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Geillinger-K\u00e4stle","sequence":"additional","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Dick","sequence":"additional","affiliation":[{"name":"Global Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gantner","sequence":"additional","affiliation":[{"name":"C.H. Boehringer Sohn AG & Co. KG, Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nickolaus","sequence":"additional","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska E.","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Immunology & Respiratory Diseases Research and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"2026012204150222600_bib1","doi-asserted-by":"crossref","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2026012204150222600_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir Res"},{"key":"2026012204150222600_bib3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"2026012204150222600_bib4","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1007\/s00018-019-03212-3","article-title":"Molecular determinants of mesenchymal cell activation in fibroproliferative diseases","volume":"76","author":"Penke","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"2026012204150222600_bib5","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012204150222600_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s43152-022-00040-9","article-title":"The vasculature in pulmonary fibrosis","volume":"3","author":"Engelbrecht","year":"2022","journal-title":"Curr Tissue Microenviron Rep"},{"key":"2026012204150222600_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1165\/rcmb.2022-0431TR","article-title":"Vascular contribution to lung repair and fibrosis","volume":"69","author":"Caporarello","year":"2023","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204150222600_bib8","doi-asserted-by":"crossref","first-page":"220206","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2026012204150222600_bib9","doi-asserted-by":"crossref","first-page":"838449","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026012204150222600_bib10","doi-asserted-by":"crossref","first-page":"00240-2022","DOI":"10.1183\/23120541.00240-2022","article-title":"Phase I studies of BI 1015550, a preferential PDE4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis","volume":"8","author":"Maher","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026012204150222600_bib11","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4b inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012204150222600_bib12","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1111\/bph.17303","article-title":"PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells","volume":"181","author":"Reininger","year":"2024","journal-title":"Br J Pharmacol"},{"key":"2026012204150222600_bib13","first-page":"A3224","article-title":"Staying in the flow: preferential PDE4B inhibitor nerandomilast (BI 1015550) improves features of vascular dysfunction in lung fibrosis in vitro and in vivo","volume":"209","author":"Reininger","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204150222600_bib14","doi-asserted-by":"crossref","first-page":"L206","DOI":"10.1152\/ajplung.00364.2021","article-title":"Characterization of a flexible AAV-DTR\/DT mouse model of acute epithelial lung injury","volume":"323","author":"Griesser","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012204150222600_bib15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1177\/0271678X20943823","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"40","author":"Percie Du Sert","year":"2020","journal-title":"J Cereb Blood Flow Metab"},{"key":"2026012204150222600_bib16","doi-asserted-by":"crossref","first-page":"e144799","DOI":"10.1172\/jci.insight.144799","article-title":"Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions","volume":"6","author":"Fortier","year":"2021","journal-title":"JCI Insight"},{"key":"2026012204150222600_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1074\/jbc.M109.038620","article-title":"Increased cAMP levels modulate transforming growth factor-\u03b2\/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions","volume":"285","author":"Schiller","year":"2010","journal-title":"J Biol Chem"},{"key":"2026012204150222600_bib18","doi-asserted-by":"crossref","first-page":"e172826","DOI":"10.1172\/JCI172826","article-title":"MAPK phosphatase 1 inhibition of p38\u03b1 within lung myofibroblasts is essential for spontaneous fibrosis resolution","volume":"134","author":"Fortier","year":"2024","journal-title":"J Clin Invest"},{"key":"2026012204150222600_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/path.1208","article-title":"MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis","volume":"198","author":"Yoshida","year":"2002","journal-title":"J Pathol"},{"key":"2026012204150222600_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-020-00367-5","article-title":"Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies","volume":"6","author":"Geraldo","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026012204150222600_bib21","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1096\/fj.201902926R","article-title":"Recapitulating idiopathic pulmonary fibrosis related alveolar epithelial dysfunction in a human iPSC-derived air-liquid interface model","volume":"34","author":"Schruf","year":"2020","journal-title":"FASEB J"},{"key":"2026012204150222600_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1096\/fj.01-0739fje","article-title":"Role of vasodilator-stimulated phosphoprotein in protein kinase A-induced changes in endothelial junctional permeability","volume":"16","author":"Comerford","year":"2002","journal-title":"FASEB J"},{"key":"2026012204150222600_bib23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nri2171","article-title":"Evolving functions of endothelial cells in inflammation","volume":"7","author":"Pober","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2026012204150222600_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pupt.2012.05.007","article-title":"cAMP regulation of airway smooth muscle function","volume":"26","author":"Billington","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"2026012204150222600_bib25","first-page":"A2226","article-title":"G-protein coupled receptor-mediated cAMP activation within lung fibroblasts is essential for spontaneous fibrosis resolution following bleomycin-induced lung injury","volume":"207","author":"Fortier","year":"2023","journal-title":"Am J Resp Crit Care Med"},{"key":"2026012204150222600_bib26","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1242\/jcs.114.24.4359","article-title":"Smad regulation in TGF-\u03b2 signal transduction","volume":"114","author":"Moustakas","year":"2001","journal-title":"J Cell Sci"},{"key":"2026012204150222600_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-017-0523-z","article-title":"Dibutyryl-cAMP attenuates pulmonary fibrosis by blocking myofibroblast differentiation via PKA\/CREB\/CBP signaling in rats with silicosis","volume":"18","author":"Liu","year":"2017","journal-title":"Respir Res"},{"key":"2026012204150222600_bib28","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.7150\/ijbs.71595","article-title":"Smad3 signatures in renal inflammation and fibrosis","volume":"18","author":"Wu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2026012204150222600_bib29","doi-asserted-by":"crossref","first-page":"35483","DOI":"10.1038\/srep35483","article-title":"TGF-\u03b2 induces p53\/Smads complex formation in the PAI-1 promoter to activate transcription","volume":"6","author":"Kawarada","year":"2016","journal-title":"Sci Rep"},{"key":"2026012204150222600_bib30","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.7150\/ijbs.40173","article-title":"Knockdown of SMAD3 inhibits the growth and enhances the radiosensitivity of lung adenocarcinoma via p21 in vitro and in vivo","volume":"16","author":"Niu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"2026012204150222600_bib31","doi-asserted-by":"crossref","first-page":"17151","DOI":"10.1074\/jbc.M114.558130","article-title":"Prostaglandin E2 inhibits \u03b1-smooth muscle actin transcription during myofibroblast differentiation via distinct mechanisms of modulation of serum response factor and myocardin-related transcription factor-A","volume":"289","author":"Penke","year":"2014","journal-title":"J Biol Chem"},{"key":"2026012204150222600_bib32","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.3390\/ijms23116270","article-title":"Smad3 phospho-isoform signaling in nonalcoholic steatohepatitis","volume":"23","author":"Yamaguchi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026012204150222600_bib33","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1111\/bph.13982","article-title":"Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis","volume":"174","author":"Herrmann","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2026012204150222600_bib34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2019.12.008","article-title":"Targeting GPCR signaling for idiopathic pulmonary fibrosis therapies","volume":"41","author":"Haak","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"2026012204150222600_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"key":"2026012204150222600_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1165\/rcmb.2011-0025RT","article-title":"Prostaglandin E2 and the pathogenesis of pulmonary fibrosis","volume":"45","author":"Bozyk","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012204150222600_bib37","doi-asserted-by":"crossref","first-page":"L810","DOI":"10.1152\/ajplung.00403.2018","article-title":"Prostaglandin E2 inhibits profibrotic function of human pulmonary fibroblasts by disrupting Ca2+ signaling","volume":"316","author":"Mukherjee","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026012204150222600_bib38","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2353\/ajpath.2010.100446","article-title":"Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice","volume":"177","author":"Huang","year":"2010","journal-title":"American J Pathol"},{"key":"2026012204150222600_bib39","doi-asserted-by":"crossref","first-page":"e172058","DOI":"10.1172\/JCI172058","article-title":"Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis","volume":"133","author":"May","year":"2023","journal-title":"J Clin Invest"},{"key":"2026012204150222600_bib40","doi-asserted-by":"crossref","first-page":"976873","DOI":"10.3389\/fphys.2022.976873","article-title":"Molecular mechanisms of lung endothelial permeability","volume":"13","author":"Parinandi","year":"2022","journal-title":"Front Physiol"},{"key":"2026012204150222600_bib41","doi-asserted-by":"crossref","first-page":"105030","DOI":"10.1016\/j.phrs.2020.105030","article-title":"Blame the signaling: role of cAMP for the resolution of inflammation","volume":"159","author":"Tavares","year":"2020","journal-title":"Pharmacol Res"},{"key":"2026012204150222600_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1183\/09031936.00060708","article-title":"MMP expression and abnormal lung permeability are important determinants of outcome in IPF","volume":"33","author":"McKeown","year":"2009","journal-title":"Eur Respir J"},{"key":"2026012204150222600_bib43","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/thorax.56.12.916","article-title":"Pulmonary 99mTc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP)","volume":"56","author":"Mogulkoc","year":"2001","journal-title":"Thorax"},{"key":"2026012204150222600_bib44","author":"Maher"},{"key":"2026012204150222600_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1165\/rcmb.2018-0313OC","article-title":"Defining the activated fibroblast population in lung fibrosis using single-cell sequencing","volume":"61","author":"Peyser","year":"2019","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["American Journal of Respiratory Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/73\/5\/700\/66193587\/ajrcmb_73_5_700.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/73\/5\/700\/66193587\/ajrcmb_73_5_700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:17:49Z","timestamp":1769073469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article\/73\/5\/700\/8405095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1165\/rcmb.2024-0614oc","relation":{},"ISSN":["1044-1549","1535-4989"],"issn-type":[{"value":"1044-1549","type":"print"},{"value":"1535-4989","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"2024-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}